title: [The mTOR inhibitor enhances chemosensitivity of androgen-independent prostate cancer cell line].
abstract: OBJECTIVE
  To investigate the effect of the mammalian target of rapamycin (mTOR) inhibitor CCI-779 on the chemosensitivity of androgen-independent prostate cancer cell line PC-3.
  
  
  METHODS
  Prostate cancer cells PC-3 were cultured and treated with CCI-779, Paclitaxel and combination of the two. Then the inhibitory effects of the three medications on the growth of the PC-3 cells were determined by MTT, and the their cell cycle and apoptosis were detected by flow cytometry.
  
  
  RESULTS
  Compared with the control group, the three medications all significantly inhibited the proliferation of the PC-3 cells, and the combined method even enhanced the effect. Flow cytometry showed that CCI-779 and Paclitaxel blocked the cell cycle mainly in the G1/G2 stage, while the combined medication mainly in the G0/G1 stage. Significantly increased apoptosis of the PC-3 cells was observed in the three medication groups as compared with the control group (P < 0.01).
  
  
  CONCLUSIONS
  CCI-779 can inhibit the proliferation of PC-3 cells and enhance the chemosensitivity of prostate cancer.
authors.affiliation: Department of Urology, Lujiang People's Hospital, Lujiang, Anhui 231500, China.
authors.forename: Jin-Sheng
authors.initials: JS
authors.lastname: Xia
authors.forename: Xian-Guo
authors.initials: XG
authors.lastname: Chen
authors.forename: Qian-Yuan
authors.initials: QY
authors.lastname: Zhuang
authors.forename: Ji-Hong
authors.initials: JH
authors.lastname: Liu
authors.forename: Zhang-Qun
authors.initials: ZQ
authors.lastname: Ye
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C401859:temsirolimus; D017239:Paclitaxel; D020123:Sirolimus